Latest filing published 04 Aug 2026 for REGENXBIO Inc., €63k.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
This profile gathers the share dealings of Steve Pakola in REGENXBIO Inc., where the filings describe the role as senior executive. Between 4 January 2021 and 1 August 2026, the trades on record add up to 23 filings.
On the market, this insider has only sold: 6 sales, €794k in total. The rest of the record consists of 15 share grants and 2 option exercises. Since January 2026: no purchases and 2 sales on the market.
Most recently, on 4 August 2026, the filings show a share grant worth €63k in REGENXBIO Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
14 of 14 declarations